DE60026877T2 - Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl - Google Patents

Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Download PDF

Info

Publication number
DE60026877T2
DE60026877T2 DE60026877T DE60026877T DE60026877T2 DE 60026877 T2 DE60026877 T2 DE 60026877T2 DE 60026877 T DE60026877 T DE 60026877T DE 60026877 T DE60026877 T DE 60026877T DE 60026877 T2 DE60026877 T2 DE 60026877T2
Authority
DE
Germany
Prior art keywords
compound
melting
formula
polymorph
amorphous
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60026877T
Other languages
German (de)
English (en)
Other versions
DE60026877D1 (de
Inventor
Dorothee Sophie Kirkland CLAS
Paul Kirkland O'SHEA
Chad Kirkland DALTON
S. Louis Rahway CROCKER
A. James Rahway MCCAULEY
D. Richard Rahway TILLYER
Ian Rahway DAVIES
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Canada Inc
Merck Sharp and Dohme LLC
Original Assignee
Merck Frosst Canada Ltd
Merck and Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd, Merck and Co Inc filed Critical Merck Frosst Canada Ltd
Application granted granted Critical
Publication of DE60026877D1 publication Critical patent/DE60026877D1/de
Publication of DE60026877T2 publication Critical patent/DE60026877T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
DE60026877T 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl Expired - Lifetime DE60026877T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16792299P 1999-11-29 1999-11-29
US167922P 1999-11-29
PCT/US2000/032353 WO2001037833A1 (en) 1999-11-29 2000-11-27 Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Publications (2)

Publication Number Publication Date
DE60026877D1 DE60026877D1 (de) 2006-05-11
DE60026877T2 true DE60026877T2 (de) 2006-11-23

Family

ID=22609368

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60026877T Expired - Lifetime DE60026877T2 (de) 1999-11-29 2000-11-27 Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl

Country Status (11)

Country Link
US (3) US6441002B1 (https=)
EP (1) EP1248618B1 (https=)
JP (1) JP4425514B2 (https=)
AT (1) ATE320809T1 (https=)
AU (1) AU776544B2 (https=)
CA (1) CA2391650C (https=)
DE (1) DE60026877T2 (https=)
DK (1) DK1248618T3 (https=)
ES (1) ES2259295T3 (https=)
PT (1) PT1248618E (https=)
WO (1) WO2001037833A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis
US6521642B2 (en) 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
WO2005085199A1 (en) * 2004-01-14 2005-09-15 Cadila Healthcare Limited Novel polymorphs of etoricoxib
PL2479166T3 (pl) 2009-02-27 2014-11-28 Cadila Healthcare Ltd Sposób otrzymywania etorykoksybu
WO2012163839A1 (en) 2011-05-27 2012-12-06 Farma Grs, D.O.O. A process for the preparation of polymorphic form i of etoricoxib
EP2773618A1 (en) 2011-11-03 2014-09-10 Cadila Healthcare Limited An improved process for the preparation of etoricoxib and polymorphs thereof
WO2013075732A1 (en) 2011-11-21 2013-05-30 Synthon Bv Process for making crystalline form i of etoricoxib
EP2601952A1 (en) 2011-12-07 2013-06-12 Zentiva, k.s. Novel pharmaceutically acceptable salts and cocrystals of 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3']bipyridinyl and their therapeutic uses
EP2831045A2 (en) * 2012-03-30 2015-02-04 Mylan Laboratories, Limited An improved process for the preparation of etoricoxib
EP2888231B1 (en) 2012-08-27 2019-01-09 Glenmark Pharmaceuticals Limited Process for preparation of crystalline etoricoxib
CN104418799A (zh) * 2013-09-03 2015-03-18 天津药物研究院 一种依托考昔的晶型及其制备方法和应用
WO2015036550A1 (en) 2013-09-13 2015-03-19 Synthon B.V. Process for making etoricoxib
CN107056691B (zh) * 2017-06-21 2020-03-10 四川尚锐生物医药有限公司 一种制备依托考昔晶型v的方法
MX2018013070A (es) 2017-12-29 2019-10-15 Gruenenthal Gmbh Combinación farmacéutica que comprende clorhidrato de tramadol de liberación extendida y etoricoxib de liberación inmediata, y su uso para el tratamiento del dolor.
CN111410629A (zh) * 2020-03-31 2020-07-14 天津大学 依托考昔溶剂化物及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5321033A (en) 1991-11-15 1994-06-14 Merck Frosst Canada, Inc. Amorphous (quinolin-2-ylmethoxy)indole compounds useful for treating inflammatory diseases
IL127441A (en) 1996-07-18 2003-02-12 Merck Frosst Canada Inc Substituted pyridines, pharmaceutical compositions comprising them and their use in the preparation of anti-inflammatory medicaments or as selective cyclooxygenase-2 inhibitors
US5861419A (en) * 1996-07-18 1999-01-19 Merck Frosst Canad, Inc. Substituted pyridines as selective cyclooxygenase-2 inhibitors
US6127545A (en) 1997-04-18 2000-10-03 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6130334A (en) 1998-04-15 2000-10-10 Merck & Co., Inc. Process for making 2-aryl-3-aryl-5-halo pyridines useful as COX-2 inhibitors
US6040450A (en) 1997-09-25 2000-03-21 Merck & Co., Inc. Process for making diaryl pyridines useful as cox-2-inhibitors
HU227627B1 (en) * 1998-04-24 2011-10-28 Merck Sharp & Dohme Process for synthesizing pyridine derivatives as cox-2 inhibitors and the intermediates
US6521642B2 (en) * 2000-05-26 2003-02-18 Merck & Co., Inc. 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
PH12001001175B1 (en) * 2000-05-26 2006-08-10 Merck Sharp & Dohme 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl- (2,3')bipyridinyl in pure crystalline form and process for synthesis

Also Published As

Publication number Publication date
US6441002B1 (en) 2002-08-27
EP1248618A4 (en) 2003-05-14
JP4425514B2 (ja) 2010-03-03
AU776544B2 (en) 2004-09-16
US20030144327A1 (en) 2003-07-31
ATE320809T1 (de) 2006-04-15
US20020198238A1 (en) 2002-12-26
EP1248618A1 (en) 2002-10-16
CA2391650A1 (en) 2001-05-31
AU1803101A (en) 2001-06-04
WO2001037833A1 (en) 2001-05-31
CA2391650C (en) 2011-01-25
DK1248618T3 (da) 2006-07-10
JP2003514859A (ja) 2003-04-22
DE60026877D1 (de) 2006-05-11
EP1248618B1 (en) 2006-03-22
PT1248618E (pt) 2006-07-31
ES2259295T3 (es) 2006-10-01

Similar Documents

Publication Publication Date Title
DE60026877T2 (de) Polymorphe, amorphe und hydratisierte formen von 5-chlor-3-(methansulfonylphenyl)-6'-methyl-[2,3']bipyridinyl
EP1660482B1 (de) 3-[(2-{ 4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1h-benzimidazol-5-carbonyl)-pyridin-2-yl-amino] -propionsäure-ethylester -methansulfonat und dessen verwendung als arzneimittel
CA2683040C (en) Polymorphic forms of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
DE69704679T2 (de) 4-phenylpiperidin-derivate
DE60215699T2 (de) Quinolinone als prostaglandin rezeptor liganden
AU2002320822A1 (en) Polymorphic forms of 1-'4-(5-cyanoindol-3-yl)butyl-4-(2-carbamoylbenzofuran-5-yl)piperazine hydrochloride
DE60024648T2 (de) Carbonsäuren und acylsulfonamide, diese verbindungen enthaltende zubereitungen und behandlungsmethoden
DE19716984A1 (de) Verfahren zur Herstellung von reinem Flupirtin-Maleat und dessen Modifikation A
US6521642B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl in pure crystalline form and process for synthesis
DE69426021T2 (de) Xamonelin-Tartrat
DE20320528U1 (de) Neue Kristallformen von Ondansetron und Arzneimittel, welche die neuen Formen enthalten
DE60116902T2 (de) Neue desloratadinsalze, verfahren zu deren synthese und diese enthaltende pharmazeutische zusammensetzungen
DE102007032612A1 (de) Polymorphe Formen von Flupirtinmaleat
DE69822882T2 (de) Thermodynamisch stabile form von (r) -3- [[(4-fluorophenyl) sulphonyl] amino] - 1,2,3,4-tetrahydro-9h-carbazole-9-propanoic acid (ramatroban)
US6858631B1 (en) Polymorphic, amorphous and hydrated forms of 5-chloro-3-(4-methanesulfonylphenyl)-6′-methyl-[2,3′]bipyridinyl
US6800647B2 (en) 5-chloro-3-(4-methanesulfonylphenyl)-6'-methyl-[2,3]bipyridinyl in pure crystalline form and process for synthesis
DE4445785A1 (de) Thermodynamisch stabile Form von N-[4-[2-(2,4-Dimethylphenoxy)-phenyl]-2-thiazolyl]-1,4,5,6-tetrahydro-2-pyrimidinamin (DTTP)
DE69027245T2 (de) Pyrrolochinolin-Derivate, ihre Verwendung in antimikrobiellen Mitteln und Verfahren zu ihrer Herstellung
WO2001044232A1 (de) Belaperidone-fumarat und dessen modifikationen
DD211342A5 (de) Verfahren zur herstellung polymorpher formen von 5-[3-(2-[2,2,2-trifluor-ethyl] guanidino)pyrazol-1-yl] valeramid

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MERCK & CO., INC., WHITEHOUSE STATION, N.J., US

Owner name: MERCK FROSST CANADA LTD., KIRKLAND, QUEBEC, CA

8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: MERCK FROSST CANADA LTD., KIRKLAND, QUEBEC, CA

Owner name: MERCK SHARP & DOHME CORP., NEW JERSEY, N.J., US

R081 Change of applicant/patentee

Ref document number: 1248618

Country of ref document: EP

Owner name: SCHERING CORPORATION, US

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., MERCK SHARP & DOHME CORP., , US

Effective date: 20121213

Ref document number: 1248618

Country of ref document: EP

Owner name: MERCK FROSST CANADA LTD., CA

Free format text: FORMER OWNER: MERCK FROSST CANADA LTD., MERCK SHARP & DOHME CORP., , US

Effective date: 20121213

R082 Change of representative

Ref document number: 1248618

Country of ref document: EP

Representative=s name: ABITZ & PARTNER, DE

Effective date: 20121213